Showing results (991-1000 of 1,009) with videos related to

Sort By:
Pageof 101
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
ESMO Open|July 15, 2025
Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanyC Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
Nature|October 9, 2024
Overconfidence in climate overshootCarl-Friedrich Schleussner, Gaurav Ganti, Quentin Lejeune, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Pageof 101